• BMS acquires Celgene for an equity value of $74bn pharmaceutical-technology
    January 04, 2019
    Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement to acquire Celgene via a cash and stock transaction with an equity value of $74bn; Celgene shares have been valued at $102.43 per share....
PharmaSources Customer Service